Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 16/20 | 0.68 |
| ▸ | KIT | P10721 | 9/20 | 0.68 |
| ▸ | PDGFRA | P16234 | 9/20 | 0.68 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.56 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.56 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.56 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.56 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.56 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.56 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.56 |
| ▸ | FLT1 | P17948 | 3/20 | 0.56 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1961077 | 0.92 | KDR (0.60) | KDRKITPDGFRAHDAC1HDAC6 | |
| SCHEMBL23587599 | 0.90 | KDR (0.56) | KDRKITPDGFRAHDAC1HDAC6 | |
| SCHEMBL18101235 | 0.89 | KDR (0.56) | KDRKITPDGFRAHDAC1HDAC6 | |
| SCHEMBL14347685 | 0.88 | KDR (0.67) | KDRKITPDGFRAHDAC1HDAC6 | |
| SCHEMBL29516846 | 0.88 | KDR (0.67) | KDRKITPDGFRAHDAC1HDAC6 | |
| Hydrochloric Acid SCHEMBL29516748 | 0.86 | KDR (0.66) | KDRKITPDGFRAHDAC1HDAC6 | |
| SCHEMBL11953494 | 0.86 | KDR (0.66) | KDRKITPDGFRAHDAC1HDAC6 | |
| SCHEMBL13849112 | 0.85 | KDR (0.65) | KDRKITPDGFRAHDAC1HDAC6 | |
| SCHEMBL20729864 | 0.85 | KDR (0.65) | KDRKITPDGFRAHDAC1HDAC6 | |
| Hydrochloric Acid SCHEMBL30817650 | 0.84 | KDR (0.64) | KDRKITPDGFRAHDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117169410-A | Method for analyzing indazole structure related substances | 南京正大天晴制药有限公司 | 2023-12-05 | — | — | CN | claimed |
| CN-116242934-A | Detection method and application of related substances of pezopanib hydrochloride intermediate PZP-M2 | 山西振东制药股份有限公司 | 2023-06-09 | — | — | CN | claimed |
| US-11299477-B2 | Process for the preparation of Pazopanib or a pharmaceutically acceptable salt thereof | LAURUS LABS LIMITED (IN) | 2022-04-12 | — | — | US | claimed |
| CN-109212042-B | Analysis method for determining toxicity impurities of pezopyr hydrochloride gene by adopting liquid chromatography-mass spectrometry | 齐鲁制药有限公司 | 2022-03-04 | — | — | CN | claimed |
| WO-2020238220-A1 | METHOD FOR PREPARING PAZOPANIB HYDROCHLORIDE | 济南爱思医药科技有限公司 | 2020-12-03 | — | — | WO | claimed |
| CN-110143951-B | Synthetic method of pazopanib hydrochloride raw material trimer impurity | 博诺康源(北京)药业科技有限公司 | 2020-11-10 | — | — | CN | claimed |
| US-20200262821-A1 | PROCESS FOR THE PREPARATION OF PAZOPANIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | LAURUS LABS LIMITED (IN) | 2020-08-20 | — | — | US | claimed |
| US-10626110-B2 | Polymorph of pazopanib hydrochloride and preparation process thereof | FORMOSA LABORATORIES, INC. (TW) | 2020-04-21 | — | — | US | claimed |
| US-20200048224-A1 | NOVEL POLYMORPH OF PAZOPANIB HYDROCHLORIDE AND PREPARATION PROCESS THEREOF | FORMOSA LABORATORIES, INC. (TW) | 2020-02-13 | — | — | US | claimed |
| CN-110028495-B | The preparation method of pazopanib hydrochloride | 济南爱思医药科技有限公司 | 2019-12-03 | — | — | CN | claimed |
| CN-110143951-A | Synthetic method of pazopanib hydrochloride raw material trimer impurity | 博诺康源(北京)药业科技有限公司 | 2019-08-20 | — | — | CN | claimed |
| CN-110028495-A | The environment-friendly preparation method thereof of pazopanib hydrochloride | 济南爱思医药科技有限公司 | 2019-07-19 | — | — | CN | claimed |
| US-20160280689-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF PAZOPANIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | LAURUS LABS LIMITED (IN) | 2016-09-29 | — | — | US | claimed |
| US-20240050429-A1 | PAZOPANIB PHARMACEUTICAL COMPOSITION, INJECTION AND PREPARATION METHOD AND USE THEREOF | Qx Therapeutics, Inc. | 2024-02-15 | — | — | US | disclosed |
| CN-117510513-A | Heterocyclic compounds having biological activity | 首药控股(北京)股份有限公司 | 2024-02-06 | — | — | CN | disclosed |
| CN-117169410-A | Method for analyzing indazole structure related substances | 南京正大天晴制药有限公司 | 2023-12-05 | — | — | CN | disclosed |
| WO-2005105094-A2 | CANCER TREATMENT METHOD | SMITHKLINE BEECHAM CORPORATION (US) | 2005-11-10 | — | — | WO | disclosed |
| EP-1515955-A2 | CHEMICAL PROCESS | SmithKline Beecham Corporation (US) | 2005-03-23 | — | — | EP | disclosed |
| US-20040242578-A1 | Pyrimidineamines as angiogenesis modulators | NOVARTIS AG (CH) | 2004-12-02 | — | — | US | disclosed |
| WO-2003106416-A2 | CHEMICAL PROCESS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242578-A1 | Pyrimidineamines as angiogenesis modulators | TYMS, TYMP, DPYD | KDR 5/4885KIT 183/4885PDGFRA 13/4885 |
| US-11299477-B2 | Process for the preparation of Pazopanib or a pharmaceutically acceptable salt thereof | JAK2, SF3B5, PDGFRB | KDR 19/4885KIT 1154/4885PDGFRA 5/4885 |
| US-10626110-B2 | Polymorph of pazopanib hydrochloride and preparation process thereof | PDGFRB, PDGFRA, PNP | KDR 5/4885KIT 882/4885PDGFRA 2/4885 |
| US-20160280689-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF PAZOPANIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | SF3B5, PDGFRB, JAK2 | KDR 10/4885KIT 1459/4885PDGFRA 4/4885 |
| US-20200048224-A1 | NOVEL POLYMORPH OF PAZOPANIB HYDROCHLORIDE AND PREPARATION PROCESS THEREOF | PDGFRB, KDR, PDGFRA | KDR 2/4885KIT 629/4885PDGFRA 3/4885 |
| US-20200262821-A1 | PROCESS FOR THE PREPARATION OF PAZOPANIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | JAK2, SF3B5, PDGFRB | KDR 18/4885KIT 1039/4885PDGFRA 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.